

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this joint announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this joint announcement.*

*This joint announcement appears for information purposes only and is not intended to and does not constitute, or form part of, any offer to purchase or subscribe for or an invitation to purchase or subscribe for any securities of the Offeror or the Company or the solicitation of any vote or approval in any jurisdiction, nor shall there be any sale, issuance or transfer of securities of the Company in any jurisdiction in contravention of applicable law.*



**Meditech Global Group Limited**  
*(Incorporated in the British Virgin Islands with limited liability)*

**GOLDEN MEDITECH HOLDINGS LIMITED**  
**金衛醫療集團有限公司**  
*(Incorporated in the Cayman Islands with limited liability)*  
**(Stock Code: 00801)**

## **JOINT ANNOUNCEMENT**

### **EXTENSION OF TIME FOR DESPATCH OF SCHEME DOCUMENT**

#### **(1) PROPOSAL FOR THE PRIVATISATION OF GOLDEN MEDITECH HOLDINGS LIMITED BY THE OFFEROR BY WAY OF A SCHEME OF ARRANGEMENT (UNDER SECTION 86 OF THE COMPANIES LAW)**

#### **(2) PROPOSED WITHDRAWAL OF LISTING**

**AND**

#### **(3) SPECIAL DEAL RELATING TO THE UNDERTAKING**

**Financial Adviser to the Offeror**

**AMASSE CAPITAL**  
**寶 積 資 本**

**Independent Financial Adviser to the Company**

 **SOMERLEY LIMITED**

Reference is made to the announcement jointly issued by Golden Meditech Holdings Limited (the “**Company**”) and Meditech Global Group Limited (the “**Offeror**”) dated 17 June 2020 (the “**Joint Announcement**”) in relation to, among other things, the proposed privatisation of the Company by the Offeror by way of a scheme of arrangement (under section 86 of the Companies Law) and the proposed withdrawal of listing of the shares of the Company from The Stock Exchange of Hong Kong Limited. Capitalised terms used herein shall have the same meanings as those defined in the Joint Announcement unless the context requires otherwise.

Pursuant to Rule 8.2 of the Takeovers Code, unless the Executive’s consent is obtained, the Scheme Document containing, among others, further details of (i) the Proposal and the Scheme, the Subscription Agreement and the Undertaking; (ii) the expected timetable; (iii) an explanatory memorandum as required under the Companies Law and the rules of the Grand Court; (iv) information regarding the Company; (v) recommendations from the Independent Board Committee with respect to the Proposal, the Scheme and the Undertaking; (vi) the letter of advice from the Independent Financial Adviser to the Independent Board Committee; and (vii) a notice of the Court Meeting and a notice of the General Meeting, together with the respective forms of proxy in relation thereto, should normally be despatched to the Shareholders within 21 days of the date of the Joint Announcement, which in this case would be on or before 8 July 2020.

As stated in the Joint Announcement, the Proposal is, and the Scheme will only become effective, subject to the fulfilment (or waiver) of, amongst other Conditions, the Scheme being approved at the Court Meeting. A hearing of the Grand Court (the “**Hearing**”) is required for the Grand Court to issue its directions for convening the Court Meeting to approve the Scheme. As additional time is required for finalising the Scheme Document (including but not limited to the letter of advice from the Independent Financial Adviser and the confirmation in relation to material changes) and to accommodate the timetable for the Hearing, the Scheme Document cannot be despatched on or before 8 July 2020.

An application has been made by the Company and the Offeror to the Executive for consent to the extension of the latest date for despatching the Scheme Document from 8 July 2020 to 26 August 2020 and the Executive has granted the consent.

A detailed timetable for the implementation of the Proposal will be set out in the Scheme Document and in the announcement to be made by the Company and the Offeror upon the despatch of the Scheme Document.

**WARNING: Shareholders and potential investors should be aware that the implementation of the Proposal is subject to the Conditions being fulfilled or waived, as applicable, and thus the Proposal may or may not be implemented and the Scheme may or may not become effective. Shareholders and potential investors should therefore exercise caution when dealing in the securities of the Company. Persons who are in doubt as to the action they should take should consult their stockbroker, bank manager, solicitor or other professional advisers.**

By order of the board of  
**Meditech Global Group Limited**  
**KAM Yuen**  
*Sole Director*

By order of the board of  
**Golden Meditech Holdings Limited**  
**Feng Wen**  
*Chairman*

Hong Kong, 8 July 2020

*As at the date of this joint announcement, the Board comprises five Directors. The executive Directors are Mr. Feng Wen (Chairman) and Mr. Leong Kim Chuan (Chief Executive); and the independent non-executive Directors are Mr. Gao Yue, Mr. Poon Tsz Hang and Mr. Daniel Foa.*

*The Directors jointly and severally accept full responsibility for the accuracy of the information contained in this joint announcement (other than information relating to the Offeror or any of the Offeror Concert Parties) and confirm, having made all reasonable inquiries, that to the best of their knowledge, opinions expressed in this joint announcement (other than opinions expressed by the Offeror or any of the Offeror Concert Parties) have been arrived at after due and careful consideration and there are no other facts not contained in this joint announcement the omission of which would make any statement in this joint announcement misleading.*

*As at the date of this joint announcement, (i) the sole director of the Offeror is Mr. Kam; (ii) the sole director of Bio Garden Inc. is Mr. Kam; (iii) the sole director of China In Shine Investment Limited is Ms. Fung Chit; (iv) the sole director of Asia Pacific MedTech (BVI) Limited is Ms. Gu Nana; and (v) the sole director of Famous Sino Limited is Mr. Wu Guangze.*

*Mr. Kam (in his capacity as the sole director of the Offeror) accepts full responsibility for the accuracy of the information contained in this joint announcement (other than information relating to the Group) and confirm, having made all reasonable inquiries, that to the best of his knowledge, opinions expressed in this joint announcement (other than opinions expressed by the Group) have been arrived at after due and careful consideration and there are no other facts not contained in this joint announcement the omission of which would make any statement in this joint announcement misleading.*

*Mr. Kam (in his capacity as the sole director of Bio Garden Inc.), Ms. Fung Chit (in her capacity as the sole director of China In Shine Investment Limited), Ms. Gu Nana (in her capacity as the sole director of Asia Pacific MedTech (BVI) Limited) and Mr. Wu Guangze (in his capacity as the sole director of Famous Sino Limited) jointly and severally accepts full responsibility for the accuracy of the information contained in this joint announcement (other than information relating to the Group) and confirm, having made all reasonable inquiries, that to the best of her/his knowledge, opinions expressed in this joint announcement (other than opinions expressed by the Group) have been arrived at after due and careful consideration and there are no other facts not contained in this joint announcement the omission of which would make any statement in this joint announcement misleading.*